Advertisement

Topics

PubMed Journal Database | Nature biotechnology RSS

21:26 EST 21st January 2018 | BioPortfolio

The US National Library of Medicine and National Institutes of Health manage PubMed.gov which comprises of more than 21 million records, papers, reports for biomedical literature, including MEDLINE, life science and medical journals, articles, reviews, reports and  books.  BioPortfolio aims to publish relevant information on published papers, clinical trials and news associated with users selected topics.

For example view all recent relevant publications on Epigenetics and associated publications and clincial trials.

Showing PubMed Articles 1–25 of 1,000+ from Nature biotechnology

Visualizing detailed postdoctoral employment trends using a new career outcome taxonomy.

Dual gene activation and knockout screen reveals directional dependencies in genetic networks.

Understanding the direction of information flow is essential for characterizing how genetic networks affect phenotypes. However, methods to find genetic interactions largely fail to reveal directional dependencies. We combine two orthogonal Cas9 proteins from Streptococcus pyogenes and Staphylococcus aureus to carry out a dual screen in which one gene is activated while a second gene is deleted in the same cell. We analyze the quantitative effects of activation and knockout to calculate genetic interaction ...

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.

Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) and consists of a fluid lipid bilayer supported by mesoporous silica micro-rods. The lipid bilayer presents membrane-bound cues for T-cell receptor stimulation and costimulation, while the micro-rods enable sustained release of soluble paracrine cues. Using anti-CD3, anti-CD28, and interleukin-2, we show that the APC-mimetic ...

Retrieval of a million high-quality, full-length microbial 16S and 18S rRNA gene sequences without primer bias.

Small subunit ribosomal RNA (SSU rRNA) genes, 16S in bacteria and 18S in eukaryotes, have been the standard phylogenetic markers used to characterize microbial diversity and evolution for decades. However, the reference databases of full-length SSU rRNA gene sequences are skewed to well-studied ecosystems and subject to primer bias and chimerism, which results in an incomplete view of the diversity present in a sample. We combine poly(A)-tailing and reverse transcription of SSU rRNA molecules with synthetic...

Corrigendum: In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.

This corrects the article DOI: 10.1038/nbt.3836.

Drug pipeline 3Q17.

Recent patents in xenotransplantation.

Will inter partes review speed US generic drug entry?

Ablynx's nanobody fragments go places antibodies cannot.

Amgen cholesterol antibody feud could kill key IP rule.

Microbial synthesis of medium-chain chemicals from renewables.

Linear, medium-chain (C8-C12) hydrocarbons are important components of fuels as well as commodity and specialty chemicals. As industrial microbes do not contain pathways to produce medium-chain chemicals, approaches such as overexpression of endogenous enzymes or deletion of competing pathways are not available to the metabolic engineer; instead, fatty acid synthesis and reversed β-oxidation are manipulated to synthesize medium-chain chemical precursors. Even so, chain lengths remain difficult to control, ...

Around the world in a month.

Corrigendum: Development and function of human innate immune cells in a humanized mouse model.

MAGE in yeast is a go.

California cracks down on stem cell cowboys.

A new crop of microbe startups raises big bucks, takes on the establishment.

When pig organs will fly.

Erratum: Revisiting the Warnock rule.

This corrects the article DOI: 10.1038/nbt.4015.

Corrigendum: Shotgun metagenomics, from sampling to analysis.

This corrects the article DOI: 10.1038/nbt.3935.

Methods, preprints and papers.

Activists bury India's GM mustard hopes.

Institutional culture is the key to team science.

Challenges and recommendations for epigenomics in precision health.

Just how good an investment is the biopharmaceutical sector?

Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most comprehensive financial analysis of this sector to date. Our systematic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification method. We find that the perfo...

The Broad and Johns Hopkins lure deep-pocketed investors.


Quick Search
Advertisement